Overview

Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis

Status:
COMPLETED

Trial end date:
2025-05-16

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with Active Ankylosing Spondylitis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat Ankylosing Spondylitis.

Phase:

PHASE3

Details

Lead Sponsor:

SPH-BIOCAD (HK) Limited

Treatments:

netakimab